Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
Jia-Lun GuanYun-Lian HuPing AnQiong HeHui LongLin ZhouZhi-Fen ChenJian-Guang XiongShi-Sheng WuXiang-Wu DingHe-Sheng LuoPei Yuan LiPublished in: Pharmacotherapy (2022)
High-dose dual therapy for H. pylori eradication had similar efficacy and compliance, fewer adverse events, and lower costs than bismuth-containing quadruple therapy for treatment-naive patients.
Keyphrases
- helicobacter pylori
- high dose
- helicobacter pylori infection
- randomized controlled trial
- end stage renal disease
- newly diagnosed
- ejection fraction
- low dose
- prognostic factors
- peritoneal dialysis
- hiv infected
- study protocol
- stem cells
- patient reported outcomes
- mesenchymal stem cells
- patient reported
- replacement therapy